For instance, in bladder cancer, transcriptomic analysis of 200 patients and five normal samples revealed IGFBP-5 as a tumor sensitivity predictor of anti-IGF therapy that inversely corelated with IGF phosphorylation pathways [89]. The gene discussed is IGF1; the disease is urinary bladder carcinoma.